MYC mRNA expression throughout the intestine is not associated with body mass index or type 2 diabetes

Research output: Contribution to journal › Comment/debate › Research

Standard

MYC mRNA expression throughout the intestine is not associated with body mass index or type 2 diabetes. / Ellegaard, Anne-Marie; Knop, Filip Krag.

In: Endocrinology, Diabetes and Metabolism, Vol. 5, No. 2, 00327, 2022.

Research output: Contribution to journal › Comment/debate › Research

Harvard

Ellegaard, A-M & Knop, FK 2022, 'MYC mRNA expression throughout the intestine is not associated with body mass index or type 2 diabetes', Endocrinology, Diabetes and Metabolism, vol. 5, no. 2, 00327. https://doi.org/10.1002/edm2.327

APA

Ellegaard, A-M., & Knop, F. K. (2022). MYC mRNA expression throughout the intestine is not associated with body mass index or type 2 diabetes. Endocrinology, Diabetes and Metabolism, 5(2), [00327]. https://doi.org/10.1002/edm2.327

Vancouver

Ellegaard A-M, Knop FK. MYC mRNA expression throughout the intestine is not associated with body mass index or type 2 diabetes. Endocrinology, Diabetes and Metabolism. 2022;5(2). 00327. https://doi.org/10.1002/edm2.327

Author

Ellegaard, Anne-Marie ; Knop, Filip Krag. / MYC mRNA expression throughout the intestine is not associated with body mass index or type 2 diabetes. In: Endocrinology, Diabetes and Metabolism. 2022 ; Vol. 5, No. 2.

Bibtex

@article{1743b728f16f492cb011c286155ab9a0,
title = "MYC mRNA expression throughout the intestine is not associated with body mass index or type 2 diabetes",
abstract = "Inspired by the prospect of intestinal MYC reduction as a putative drug target against metabolic disorders, we investigated MYC mRNA expression in intestinal mucosa biopsies sampled using double-balloon enteroscopy along the entire intestinal tract of 12 patients with type 2 diabetes and 12 matched healthy controls. In these individuals with body mass index (BMI) ranging from 20 to 31 kg/m(2), the mean MYC mRNA expression varied along the intestine with the lowest level observed at the distal small intestine and the greatest expression levels in the proximal small intestine and in the colon. We do not see a correlation between intestinal mucosal MYC mRNA expression and BMI or glycaemic control, and thus, our findings do not support the hypothesis of intestinal MYC as a putative drug target against obesity and metabolic diseases.",
keywords = "mRNA expression, obesity, type 2 diabetes",
author = "Anne-Marie Ellegaard and Knop, {Filip Krag}",
year = "2022",
doi = "10.1002/edm2.327",
language = "English",
volume = "5",
journal = "Endocrinology, Diabetes and Metabolism",
issn = "2398-9238",
publisher = "Wiley",
number = "2",

}

RIS

TY - JOUR

T1 - MYC mRNA expression throughout the intestine is not associated with body mass index or type 2 diabetes

AU - Ellegaard, Anne-Marie

AU - Knop, Filip Krag

PY - 2022

Y1 - 2022

N2 - Inspired by the prospect of intestinal MYC reduction as a putative drug target against metabolic disorders, we investigated MYC mRNA expression in intestinal mucosa biopsies sampled using double-balloon enteroscopy along the entire intestinal tract of 12 patients with type 2 diabetes and 12 matched healthy controls. In these individuals with body mass index (BMI) ranging from 20 to 31 kg/m(2), the mean MYC mRNA expression varied along the intestine with the lowest level observed at the distal small intestine and the greatest expression levels in the proximal small intestine and in the colon. We do not see a correlation between intestinal mucosal MYC mRNA expression and BMI or glycaemic control, and thus, our findings do not support the hypothesis of intestinal MYC as a putative drug target against obesity and metabolic diseases.

AB - Inspired by the prospect of intestinal MYC reduction as a putative drug target against metabolic disorders, we investigated MYC mRNA expression in intestinal mucosa biopsies sampled using double-balloon enteroscopy along the entire intestinal tract of 12 patients with type 2 diabetes and 12 matched healthy controls. In these individuals with body mass index (BMI) ranging from 20 to 31 kg/m(2), the mean MYC mRNA expression varied along the intestine with the lowest level observed at the distal small intestine and the greatest expression levels in the proximal small intestine and in the colon. We do not see a correlation between intestinal mucosal MYC mRNA expression and BMI or glycaemic control, and thus, our findings do not support the hypothesis of intestinal MYC as a putative drug target against obesity and metabolic diseases.

KW - mRNA expression

KW - obesity

KW - type 2 diabetes

U2 - 10.1002/edm2.327

DO - 10.1002/edm2.327

M3 - Comment/debate

C2 - 35182044

VL - 5

JO - Endocrinology, Diabetes and Metabolism

JF - Endocrinology, Diabetes and Metabolism

SN - 2398-9238

IS - 2

M1 - 00327

ER -

ID: 298982220